Vaccine Ontology
1106 terms(s) returned
Term Type: Class | Record: 1051 to 1100 of 1106 Records | Page: 22 of 23, First Previous Next Last | Show Records Per Page |
- human age 7 to 10 years at vaccination
- human age 7 to 11 months at vaccination
- human age range at vaccination
- human age within one month at vaccination
- human albumin cell culture residual in vaccine
- human apo B-100 peptide-2 protein vaccine
- human child age range at vaccination
- human gene
- human ifng
- human immunization objective
- human immunodeficiency virus infectious disease
- human immunodeficiency virus vaccine
- human influenza A (H1N1) virus vaccine
- human influenza A (H1N1)-like virus vaccine
- human influenza A (H3N2) virus vaccine
- human influenza A (H3N2)-like virus vaccine
- human influenza B virus vaccine
- human influenza B-like virus
- human influenza virus vaccine
- human leukocyte antigen class I-modified peptide vaccine
- human metapneumovirus
- human metapneumovirus G protein mutant vaccine
- human metapneumovirus M2-2 mutant vaccine
- human metapneumovirus vaccine
- human papilloma virus vaccine, bivalent
- human papilloma virus vaccine, quadrivalent
- human papillomavirus 9-valent vaccine
- human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine 0.04 MG/ML / human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine 0.04 MG/ML Injectable Suspension
- human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine 0.04 MG/ML / human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine 0.04 MG/ML Injectable Suspension [Cervarix]
- human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine 0.04 MG/ML / human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine 0.04 MG/ML Prefilled Syringe
- human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine 0.04 MG/ML / human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine 0.04 MG/ML Prefilled Syringe [Cervarix]
- human papillomavirus vaccine
- human parasite role
- human protein
- human rabies vaccine from Chicken fibroblast culture
- human respiratory syncytial virus
- human senior age range at vaccination
- human serum albumin
- human serum albumin vaccine additive
- human serum cell culture residual in vaccine
- human vaccinee
- human vaccinee at age 2-17 years old
- human vaccinee population
- human vaccinee population at age 2-17 years old
- human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension
- human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension [RotaTeq]
- human-bovine reassortant rotavirus strain G1 vaccine 1100000 UNT/ML / human-bovine reassortant rotavirus strain G2 vaccine 1400000 UNT/ML / human-bovine reassortant rotavirus strain G3 vaccine 1100000 UNT/ML / human-bovine reassortant rotavirus strain G4 vaccine 1000000 UNT/ML / human-bovine reassortant rotavirus strain P1A[8] vaccine 1150000 UNT/ML Oral Suspension
- hypersensitity to arginine
- hypersensitity to gelatin
- hypersensitivity to antibiotic